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ABSTRACT
Context Metformin induced AMP-activated protein kinase (AMPK) and protected neurons in
cerebral ischaemia.
Objective This study examined pretreatment with metformin and activation of AMPK in molecular
and behavioral levels associated with memory.
Materials and methods Rats were pretreated with metformin (200mg/kg) for 2 weeks and 4-
vessels occlusion global cerebral ischaemia was induced. Three days after ischaemia, memory
improvement was done by passive avoidance task and neurological scores were evaluated. The
amount of Brain-Derived Neurotropic Factor (BDNF) and phosphorylated and total P70S6 kinase
(P70S6K) were measured.
Results Pretreatment with metformin (met) in the met + ischaemia/reperfusion (I/R) group reduced
latency time for enter to dark chamber compared with the sham group (p50.001) and increased
latency time compared with the I/R group (p50.001). Injection of Compound C (CC) (as an AMPK
inhibitor) concomitant with metformin reduced latency time in I/R rats compared with the I/R +met
group (p50.05). Neurological scores were reduced in met treated rats compared with the sham
group. Pretreatment with metformin in I/R animals reduced levels of pro-BDNF compared with the
I/R group (p50.001) but increased that compared with the sham group (p50.001). The level of
pro-BDNF decreased in the met +CC+ I/R group compared with the met + I/R group (p50.01).
Pretreatment with metformin in I/R animals significantly increased P70S6K compared with the I/R
group (p50.001).
Conclusion Short-term memory in ischaemic rats treated with metformin increased step-through
latency; sensory-motor evaluation was applied and a group of ischaemia rats that were pretreated
with metformin showed high levels of BDNF, P70S6K that seemed to be due to increasing AMPK.
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Introduction
Cerebral ischaemia is the second cause of death and one
of the reasons for the prolonged neurological disorders
and dementia in the world (Li et al. 2014). Many lines of
evidence indicated that nearly 87% of brain strokes were
ischaemia (Truong et al. 2012). Acute cerbral ischaemia
due to the occlusion of intracranial vessels leads to a high
rate of mortality and is generally considered to be
heterogeneous and multi-factorial disorder (Dichgans
2007; Ajami et al. 2011; Walcott et al. 2013). There are
two types of cerebral ischaemia: focal and global cerebral
ischaemia. In focal cerebral ischaemia/reperfusion (I/R),
blood flow interrupted in some areas of the brain and, in
global cerebral I/R, interruption of cerebral blood flow
occurs when patients undergo cardiac arrest, shock or
respiratory arrest, and this is usually associated with wide
ranging neuronal death in the hippocampus, cortex and
striatum (Petito et al. 1987; Globus et al. 1991; Zare
Mehrjerdi et al. 2013; Ashabi et al. 2014).
The vulnerable areas of the brain which are damaged
during global cerebral I/R are involved in memory and
learning processes (Vorhees & Williams 2014). Clinical
and experimental data have revealed that vascular
dementia during global cerebral ischaemia (Cummins
et al. 1988; Wu et al. 2009).
Metformin is one of the major anti-diabetic drugs
used for hyperglycaemia. Metformin activates AMP-
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activated protein kinase (AMPK) by phosphorylation of
the Thr172 residue (Hardie 2008). Recently, a wide range
of therapeutic actions of metformin against brain
vascular disruption and cerebral cancer cortexes have
been determined (Jun et al. 2015). Metformin improved
learning and memory deficits in diabetic models,
Alzheimer’s and Parkinson’s diseases, which many
researchers agree relates to the activation of AMPK
by metformin (Wilson & Cook 1994; DiTacchio et al.
2015; Chen et al. 2016).
Collected data from our laboratory have reported that
metformin induced its protective role by the phosphor-
ylation of AMPK. Metformin reduced apoptosis and
enhanced the levels of antioxidants in the hippocampus
(Ashabi et al. 2014, 2015). According to our recent paper
(Farbood et al. 2015), metformin modulated alterations
of cerebral blood flow during and after ischaemia and
then facilitated the activity of neuronal discharge.
Near relations among synaptic plasticity and memory
regulatory proteins [such as Brain-Derived Neurotrophic
Factor (BDNF), P70S6 kinase (P70S6K)] and AMPKwere
detected (Ishizuka et al. 2013). However, on one hand, a
distinct mechanism of AMPK related to expression of
BDNF is under consideration (Ishizuka et al. 2013). On
the other hand, some data have shown that AMPK
directly activated BDNF and increased long-term potenti-
ation (LTP) in hippocampal neurons (Potter et al. 2010).
Indeed, many events underlying plasticity are related to
protein translation. Phosphorylation of P70S6K leads to
mRNA transcription and protein synthesis which finally
activates other kinases such as mitogen activated protein
kinase and phosphoinositide 3-kinase and so enhances
viability of the cells (Lehman et al. 2003; Lu 2003). In this
respect, the signalling pathway of AMPK/P70S6K through
modulation of mammalian target of rapamycin was
interestingly documented in carcinoma cells (Zhang
et al. 2014; Plews et al. 2015); while unfortunately, there
was no evidence in the brain study.
The main idea of the present study was to investigate
the role of metformin against global cerebral ischaemia
focused on learning andmemory.We have shown the role
of activation and/or inhibition of AMPK on memory
improvement by behavioural assessment (passive avoid-
ance performance). Then, BDNF and activation of
P70S6K were detected in the hippocampal neurons in
the presence of metformin or in the inhibition of AMPK.
Materials and methods
Animals
Adult male Wister rats were kept in cages under
standard conditions (22 ± 2 C), humidity and a 12 h
light/dark cycle (light on 07:00–19:00), with food and
water provided ad libitum. Experimentation was
approved by the Ethics Committee of Ahvaz
Jundishapur University of Medical Sciences in accord-
ance with international guidelines for animal
experiments.
Experimental design
The rats were randomly divided into eight groups:
(1) ‘‘Sham’’, (2) metformin (200mg/kg); ‘‘Met’’, (3) com-
pound C (CC); ‘‘CC’’, (4) metformin and CC;
‘‘Met +CC’’, (5) ischaemia/reperfusion; ‘‘I/R’’, (6) met
pretreatment plus I/R; ‘‘Met + I/R’’, (7) CC and I/R;
‘‘CC+ I/R’’, (8) met pretreatment plus CC and I/R
‘‘Met +CC+ I/R’’.
Preparation and administration of drugs
Metformin (200mg/kg) was dissolved in the phosphate
buffer saline (PBS, 0.1 M) and gavage was performing
once daily for 14 d (Ashabi et al. 2014). On the 13th day,
the vertebra arteries were coagulated and, on the 14th
day, common carotid artery (CCA) was clipped for
30min. CC was dissolved in DMSO 10% and aliquots of
CC at a concentration of 5 mg/mL prepared in PBS (0.1
M) for an intravenous (5mL) injection at 30min before
induction of cerebral ischaemia (14th day) (Figure 1).
Surgical procedure
Rats underwent transient forebrain global ischaemia as
described by Pulsinelli and Brierley (1979). Briefly, on
the first day, rats were anesthetized by chloral hydrate
(400mg/kg). A sterile string was loosely placed around
each CCA without interrupting carotid blood flow and
the incision was sutured. Both vertebral arteries were
permanently electro coagulated. All changes in cerebral
blood flow were monitored by laser Doppler Flowmetry
whereas cerebral blood flow was less than 25%, the rats
were used as global cerebral ischaemia ones. Seventy-two
hour reperfusion was initiated by opening the carotid
clamps after 30min of ischaemia. Sham surgery involved
exposure of common carotid and vertebral arteries.
Rectal temperature was monitored (Citizen-513w) and
kept at 37 C by surface heating and cooling during
surgery.
Neurological scores and experimental groups
Neurological outcomes were assessed using standard
neurological score parameters (a maximum score of 25)
(Shi et al. 2011). In brief, the symptoms of roughed hair
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raising, movement decreasing, improving the response to
ear-palpating and eyelid ptosis, were 1 point, separately
for each other and splayed-out hind limb, eye patency,
circulating around body, hooked position, and clonus
were 3 points, respectively; and myasthenia of limbs was
6 points. The first total scores were obtained after being
conscious immediately after reperfusion. Twenty-four
hours later, the second neurological scores were
examined. The higher score showed the more neuro-
logical damage (Shi et al. 2011).
Passive avoidance task
The two-way shuttle box instrument (ST-5500, Borj
Sanat Co., Tehran, Iran) has been used for this test,
which was formed with two adjacent Plexiglas boxes of
identical sizes (27 cm 14.5 cm 14 cm) with plexus
floors. The floors from two compartments have been
covered with stainless steel bars (2mm diameter) are
separated by 1 cm distance. The bright compartment was
lightened by a 5 W lamp attached on the wall, just under
a mobile transparent Plexiglas roof. For passive avoid-
ance test, Tamburella method was used with little
modification (Lipton & Rosenberg 1994; Mansouri
et al. 2013). The procedure was performed in 3 days,
on the first day; the rats were adapted for recognition of
compartments. Each rat was allowed over a period of
10min adaptation to free access to either bright or dark
compartment to avoid training box after being placed in
a shuttle box (to make familiar with tools). On the
second day, the rats were placed in the bright compart-
ment and, 10 s later, the sliding door was elevated, and
latency of step-down was recorded as a learning phase
(initial latency). After entering the dark compartment,
the door was closed and when the rats touched the grid
by all four paws, a low-level electric shock (0.3mA, 3 s)
was delivered. After 3min, the rats were removed from
the dark compartment and were placed in their home
cage. On the third day, in order to assess short-term
memory, they were placed in the bright chamber again,
and, 10 s later, the sliding door went up, the latency to
enter the dark compartment (step-through latency) and
the time duration in a dark chamber were recorded. The
cut-off time was 300 s and no shock was delivered on this
day (Lipton & Rosenberg 1994; Mansouri et al. 2013).
Sacrifice and tissue preparation
After 72 h reperfusion, each group (n¼ 6) was killed by
asphyxiation with CO2. The rats were decapitated, their
brains were removed and the hippocampi were isolated
on ice, frozen in liquid nitrogen and stored at 80 C for
Western blotting assay.
Western blotting
The hippocampi of the brains were dissected in lysis-
buffer containing protease inhibitor cocktails. Total
protein extract was collected after centrifuging at
13 000 g for 5min. Protein concentrations in collected
supernatant were assayed using the Bradford method
(Bradford 1976). Standard plots were generated using
bovine serum albumin. Then, the total proteins (60 mg)
were electrophoresed on 12% SDS-PAGE gels and then
transferred to poly vinylidine fluoride (PVDF)
membranes and probed with specific antibodies.
Immune-reactive polypeptides were detected by
chemo-luminescence using enhanced electro-chemo-
luminescence (ECL) reagents and a subsequent auto-
radiography. A densitometry scan of films was
Figure 1. Outline scheme of experimental designs. Rats were pretreated with metformin over 14 d and on days 13 and 14, the 4VO
surgery was done. On the day 17, the behavioural tests for passive avoidance task and neurological scores were evaluated and rats
were scarified for molecular measurements (CCA, common carotid arteries; VA, vertebral arteries; CC, compound C).
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performed to quantify the results. Finally data analysis
was done by Image J software (NIH, Bethesda, MD),
measuring integrated densities of obtained bands after
background subtraction.
Statistical analysis
All data were expressed as mean ± SEM. The difference
between data was assessed using one-way ANOVA
followed by Tukey HSD as a post-test in SPSS 16.0
software (SPSS Inc., Chicago, IL). p Values50.05 were
considered statistically significant.
Results
Metformin increased neurological scores in the
ischaemic rats in two measured time-points
The rats were scored immediately after reperfusion and
24 h after reperfusion. As shown in Table 1, neurological
scores were 1.50 ± 0.4 in the sham-operated group
immediately after reperfusion that was significantly
different with the I/R group (p50.001). Neurological
scores were reduced in the met + I/R group compared
with the I/R group immediately after reperfusion
(p50.001). The neurological scores increased in the
met +CC+ I/R group compared with the met + I/R
group immediately after reperfusion (p50.001).
Neurological scores were zero in the sham, met, CC
and met +CC groups, 24 h after reperfusion. The
neurological outcomes increased in the met + I/R group
compared with the I/R group 24 h after reperfusion
(p50.001). Neurological outcomes increased in the
met +CC+ I/R group compared with the met + I/R
group 24 h after reperfusion (p50.001) (Table 1).
Evaluation of metformin role in the passive
avoidance task against cerebral I/R animals
In Figure 2(A), step-through latency time reduced in the
I/R group compared with the sham group (p50.001).
Also, spent time increased in a dark chamber in the I/R
group compared with the sham group (p50.001).
Pretreatment of rats with metformin in the
metformin + I/R group increased the time of latency in
dark chamber compared with the sham group (p50.001)
and compared with the I/R group (p50.001, Figure 2B).
It is expected that in ischemic rats, which pretreated with
metformin, spent time had reduced in a dark chamber
compared with the I/R group (p50.001). Administration
of the metformin group compared with the sham group
has no significant role on memory and learning in the
passive avoidance test (p40.05).
Inhibition of AMPK by CC reversed the beneficial
effects of metformin in the passive avoidance
task
The latency time reduced in ischemic animals which
were treated with CC+metformin and spent time
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Figure 2. Evaluated effects of administration of metformin and
CC on step through latency in ischemic rats. (A) Latency time to
the dark chamber was detected for 5min and expressed as
seconds. (B) Time spent in dark chamber was recorded over
5min. Bars indicate the mean ± SEM. ***p50.001 versus the
sham group, ##p50.01, ###p50.001 versus the I/R group.
$p50.05 versus the met + I/R group. Met, metformin
(200mg/kg); CC, compound C; I/R, ischaemia/reperfusion.
Table. 1. Metformin improves neurological scores in the global
cerebral ischaemia/reperfusion models.
Experimental
groups
Neurological scores
immediately
after reperfusion
Neurological scores 24 h
after reperfusion
Sham 1.50 ± 0.4 0
Met 1.75 ± 0.2 0
CC 1.33 ± 0.6 0
Met + CC 1.49 ± 0.4 0
I/R 18.47 ± 0.9*** 19.77 ± 4.5***
Met + I/R 13.59 ± 1.4### 11.07 ± 4.9###
CC+ I/R 18.66 ± 0.8 17.34 ± 3.1
Met + CC+ I/R 17.82 ± 0.8$$$ 16.91 ± 3.4$$$
Second column indicated neurological scores directly in reperfusion phase.
Third column showed neurological scores after 24 h reperfusion. Data were
shown as means ± SEM.
***p50.001 versus the sham group,
###p50.001 versus the I/R group.
$$$p50.001 versus the met + I/R group. Met: metformin; CC: compound c;
I/R: ischaemia/reperfusion.
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increased in the dark chamber compared with the sham
group (p50.001 for both, Figure 2A and B). In addition,
the treatment of ischemic animals by CC+metformin
significantly increased latency time and the time reduced
in a dark chamber compared with the metformin + I/R
group (p50.05 for both, Figure 2A and B). Besides,
injection of CC alone has no effect on latency time
compared with the sham group (p40.05).
The role of metformin on pro-BDNF levels in
hippocampus of I/R rats
As shown in Figure 3(A) and (B), the results showed that
the level of pro-BDNF increased in the I/R group
compared with the sham group (p50.001). Pretreatment
of I/R animals by metformin reduced the level of
pro-BDNF compared with the I/R group (p50.001) but
it significantly increased compared with the sham group
(p50.001).
Inhibition of AMPK reduced the action of met-
formin on pro-BDNF levels in I/R rats
Pretreatment of I/R animals by CC or CC+metformin
did not have significant changes in the level of pro-
BDNF compared with the I/R group (p40.05) but these
groups had a statistical difference compared with the
sham group (p50.001). The level of pro-BDNF
increased in the CC+metformin + I/R group compared
with the met + I/R group (p50.001, Figure 3A and B).
Activation of AMPK by metformin effects on
phosphorylation of P70S6K after I/R
As shown in Figure 4(A) and (B), data revealed that the
level of phospho-P70S6K/total P70S6K reduced in the I/
R group compared with the sham group (p50.001).
Pretreatment of I/R animals by metformin enhanced the
levels of phospho-P70S6K/total P70S6K compared with
the I/R group (p50.001).
Inhibition of AMPK effects on phosphorylation of
P70S6K followed by the model of cerebral
ischaemia
Pretreatment of I/R animals by CC or CC+metformin
compared with the I/R group did not have significant
changes on P70S6K (p40.05) but these groups have
statistical differences compared with the sham group
(p50.001). The level of phospho-P70S6K decreased in
the CC+metformin + I/R group compared with the
met + I/R group (p50.01) (Figure 4A and B).
Discussion
This study explained the role of metformin in improving
memory function in the global cerebral I/R. Besides,
recent investigations revealed that metformin induced
phosphorylation of AMPK and consequently increased
neurological scores as well as memory and some of
molecules involved in cognition. Metformin increased
BDNF and P70S6K in hippocampal neurons and
enhanced the formation of memory in passive avoidance
task. As expected, in line with our previous studies,
AMPK might be responsible for the protective function
of metformin.
One of the main disruptive roles of cerebral ischaemia
was neurovascular damage in which blood–brain-barrier
(BBB) and reactive hyperaemia impaired after reperfu-
sion. The vascular damage considered in the patho-
physiology of cerebral ischaemia and impaired neuronal
homeostasis in the brain. Our previous findings declared
that neuronal homeostasis has impaired through BBB
disruption and increased reactive hypermedia (Farbood
et al. 2015).
The protective role of metformin in the neuronal
homeostasis and associated electrophysiological activity
was obtained in our past findings (Ashabi et al. 2014;
Farbood et al. 2015). Indeed, we suggested that activation
of AMPK through treatment by metformin increased
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Figure 3. Western blot analysis to measure the effect of
metformin pretreatment on the mature BDNF levels in the
hippocampus. (A) Western blots for pro-BDNF are shown. (B) The
density of pro-BDNF bands was measured and their ratio was
calculated. Bars indicate the mean ± SEM. ***p50.001 versus the
sham group, ###p50.01, ###p50.001 versus the I/R group,
$$$p50.001 versus the met + I/R group. Met, metformin
(200mg/kg); CC, compound C; I/R, ischaemia/reperfusion.
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locomotor performance in behavioural data (Sarkaki
et al. 2015). So, we were planning to investigate the role
of metformin in the memory function in behavioural and
molecular process. Brain damage followed by global
cerebral ischaemia which raised the behavioural and
pathophysiological deficits. Neurological outcomes were
one of the major indicators of cerebral I/R (Lenzser et al.
2005). Metformin increased neurological scores and
injection of CC plus metformin reduced neurological
scores which determined the protective role of AMPK in
global cerebral ischaemia.
According to our previous reports, the sensory motor
functions were improved by metformin (Sarkaki et al.
2015) and the protocol introduced by Shi et al. (2011)
while revealed additional methods in neurological scores
assessments. Subsequently, we declared the role of
metformin treatment on learning and memory; passive
avoidance test presented as the behavioral method in
many studies of learning and memory, probably because
it required little specialized training for subjects, and
results are available quickly (Wilson & Cook 1994).
Here, behavioural assessments using passive avoid-
ance test showed that metformin increased short-term
memory which impaired over ischaemia and also
determined the importance of activation of AMPK by
CC injection (reversed role of CC versus metformin).
The therapeutic potential of metformin against oxidative
damages to brain tissue such as neurodegenerative
diseases was accepted and our results confirmed previous
works (Ishizuka et al. 2013; Lennox et al. 2014; Mousavi
et al. 2015).
In the molecular step, we focused on neurotrophins in
the brain, neurotrophic factors could play a functional
role in the adult brain, given that trophic signals
protected target innervations, improved cell viability,
plasticity and neuronal regeneration, controlled synthesis
of the neurotransmitter and the neuronal excitability
under oxidative condition (Fahnestock et al. 2002).
BDNF is one of the most important neurotrophin
factors in the brain and clearly demonstrated both in
vitro and in vivo whereas reduction of BDNF leading to
neuronal atrophy and finally death. Like other neuro-
trophins, a pro-BDNF was cleaved to a mature-BDNF
(m-BDNF) in the endoplasmic reticulum or in other
way, pro-BDNF is released into the extracellular envir-
onment and cleaved by plasmin (Barker 2009). Some
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Figure 4. The western blotting analysis was used to measure the effect of pretreatment with metformin on the phosphorylated
P70S6K, total P70S6K levels in the hippocampus. (A) Western blots for phosphorylated P70S6K, total P70S6K are shown. (B) The
density of phosphorylated P70S6K to total P70S6K bands was measured and their ratio was calculated. Bars indicate the mean ± SEM.
***p50.001 versus the sham group, ###p50.001 versus the I/R group, $$p50.01 versus the met + I/R group. Met, metformin
(200mg/kg); CC, compound C; I/R, ischaemia/reperfusion.
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studies have demonstrated that the pro-BDNF and the
m-BDNF had opposite biological potentials (Barker
2009; Yeh et al. 2015), while other studies indicated
that pro-BDNF and m-BDNF collaborated with each
other in the neurodegenerative diseases (Fahnestock
et al. 2002).
Our data indicated that the levels of pro-BDNF were
increased during cerebral I/R and metformin decreased
hippocampal level of BDNF. Current results confirmed
previous studies that the pro-BDNF and the m-BDNF in
the neuronal contexts presented opposite functions
(Numakawa et al. 2010). Tsai et al. reported that the
neuronal apoptosis improved in high levels of pro-BDNF
(Tsai 2007). However, the pro-BNDF cleaved to m-
BDNF by several enzymes such as Furin (Lu 2003); this
process may be disrupted during cerebral ischaemia and
metformin administration has recovered cellular
enzymes in Golgi apparatus and consequently decreased
the level of pro-BDNF, which means that m-BDNF
might be increased after pretreatment by metformin.
Also, injection of CC reversed the role of metformin
and activation of AMPK which was consistent with our
previous findings about the role of AMPK in the I/R
(Ashabi et al. 2014, 2015). Unfortunately, our selected
antibody could not detect m-BDNF in the hippocampus
but according to mentioned reports and determined
phosphorylation of P70S6K, the level of AMPK/BDNF
reduced during forebrain ischaemia.
P70S6K is one of the last downstream proteins that
was phosphorylated through activation of BDNF and
enhanced the plasticity in degenerated regions of the
brain (Fang et al. 2013; Koskimaki et al. 2015). The ratio
of phospho-P70S6K/total-P70S6K reduced in the I/R
group and probably metformin induction increased
phospho-P70S6K/total-P70S6K levels through AMPK
activation. Zhou et al. (2010) demonstrated the role of
BDNF on phosphorylation of P70S6K in the neurons;
the current study presented activation of AMPK as
activation of one of the up-stream proteins in this
pathway against global cerebral I/R. However, Ishizuka
et al. (2013) established the role of phosphorylation of
AMPK on BDNF/P70S6K pathways in vitro and simi-
larly our data agreed with Ishizuka findings in vivo.
Conclusion
In conclusion, accordance with our electrophysiological
assessments which identified the advantages of metfor-
min therapy effects on neuronal discharge activity
(Farbood et al. 2015) and LTP (unpublished data) in I/
R rats, we continued to investigate the neurological
outcome, learning and memory improvements in behav-
ioural aspect and moreover, detected the memory related
molecules in the brain. Both behavioural and molecular
performances showed the protective effect of metformin
in memory formation and neuronal plasticity in the
hippocampus. Short-term memory which measured by
step-through test was improved in ischaemic rats were
treated by metformin and the level of BDNF and
phosphorylation of P70S6K were increased through
activation of AMPK which suggested the AMPK/
BDNF/P70S6K pathway in an experimental model of
the global cerebral ischaemia. However, post treatment
by metformin should be examined to accept our working
hypothesis in metformin therapy.
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